21-hydroxylase deficiency
Conditions
Interventions
case series:None
Sponsors
Shenzhen Children's Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 3 Years
Inclusion criteria
Inclusion criteria: 1. Children with 21-OHD who have been diagnosed by genetics before 2021-12-31; 2. The karyotype is consistent with the rearing sex; 3. After the diagnosis, they all received regular glucocorticoid therapy (limited to hydrocortisone acetate tablets ± 9a-fluorocortisone), and the dose is not limited; 4. Regular follow-up, with inspection and medication (follow-up time requirements: =37 weeks and <42 weeks), birth weight (2500-4000g), and the mother did not receive hormone therapy during pregnancy; 7. Taking the height and bone age of the child at 3 years old as the end point, the end point can be reached.
Exclusion criteria
Exclusion criteria: 1. Suffering from diseases or other chronic diseases that affect physical growth; 2. Long-term use of other drugs or the use of growth hormone, gonadotropin-releasing hormone analogs, aromatase inhibitors, androgen blockers, inhaled/topical hormone-containing drugs or a combination of the above drugs; 3. Lack of relevant birth history, children with familial short stature or unable to provide family history; 4. Infants and young children with central precocious puberty, or those who mistakenly take estrogen drugs or use hormone drugs or take supplements/Chinese herbal medicine soup during infancy and young children become peripheral precocious puberty; 5. Psychomotor retardation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum steroid hormones level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone age;Drug dosage; | — |
Countries
China
Contacts
Public ContactLiang Liyang
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Outcome results
None listed